Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from MacroGenics, Inc., Puma Biotechnology Inc., and Seattle Genetics Inc.

Community Practice Connections™: Meeting Key Unmet Clinical Needs in HER2-Positive Breast Cancer: Aligning the Data with Strategy to Improve Patient Outcomes

Release Date: May 31, 2019
Expiration Date: May 31, 2020
Media: Internet - based

Activity Overview

Survival outcomes for patients with HER2-positive breast cancer have improved with the advent of HER2-targeted therapies. However, many important clinically unmet needs remain in the early and advanced HER2-positive disease settings, including determination of how to best apply HER2-targeted agents and other therapeutic approaches based upon individual patient- and disease-related factors. Guidelines for assessment of HER2 status continue to evolve, and it is vital for practicing clinicians to be familiar with recent changes in order to make informed management decisions. Resistance to HER2 targeting remains another clinical challenge, and exploration of newer treatment options to help address this obstacle remains an area of active clinical investigation. Recent evidence has also shed light on treatment sequencing, as well as strategies to mitigate potential treatment-associated adverse events for patients with HER2-positive breast cancer, and busy clinicians should be aware of this evidence to optimize outcomes.

This continuing medical education activity (CME) will help you address these and other challenges that you may be facing with your patients. Physicians’ Education Resource is proud to present Community Practice Connections™: Meeting Key Unmet Clinical Needs in HER2-Positive Breast Cancer: Aligning the Data with Strategy to Improve Patient Outcomes, featuring the perspectives of clinical experts in the management of patients with HER2-positive breast cancer, who will explore various aspects of patient assessment and treatment.

Benefits of Participating

  • Enhance your understanding of recent guidelines pertaining to assessment of HER2 status.
  • Gain insights into recent studies that may improve outcomes for your patients with HER2-positive breast cancer.
  • See the big picture regarding current and possible future indications for HER2-directed agents in the management of HER2-positive breast cancer.

CME Activity Table of Contents

  • Pretest
  • Module 1: HER2 Testing
  • Module 2: Management of HER2-Positive Breast Cancer
  • Posttest, evaluation and request for credit

Acknowledgement of Commercial Support

This activity is supported by educational grants from MacroGenics, Inc., Puma Biotechnology Inc., and Seattle Genetics Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is directed toward medical and surgical oncologists who treat patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, pathologists, radiation oncologists, and other healthcare professionals (HCPs) involved in the management of patients with breast cancer will also be invited to participate.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Evaluate clinical trial data regarding current and emerging therapeutics for HER2-positive breast cancer, including adjuvant and metastatic settings.
  • Explain recent updates to guidelines for HER2 testing and improved risk stratification in HER2-positive breast cancer.
  • Identify strategies to mitigate adverse events associated with therapeutics used for the treatment of HER2-positive breast cancer.
  • Place emerging data in the context of clinical scenarios for improved outcomes in treating patients with HER2-positive breast cancer

Faculty, Staff, and Planners’ Disclosures

Debu Tripathy
Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Novartis; Consultant: Nektar, Novartis, Pfizer.

Hope S. Rugo
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant/Research Support: Pfizer, Merck, Novartis, Lilly, Genentech, OBI Pharma, Plexxikon, Odonate, Daiichi Sankyo, Eisai, MacroGenics.

Mohammad Jahanzeb
Mohammad Jahanzeb, MD, FACP, FASCO
Medical Director, UM Sylvester Deerfield Campus
Associate Center Director for Community Outreach
Sylvester Comprehensive Cancer Center
University of Miami, Miller School of Medicine
Deerfield Beach, FL

Disclosures: Grant/Research Support: Lilly, Boehringer Ingelheim, Genentech, Callisto; Consultant: Novartis, Genentech, Pfizer, Ipsen, Roche.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By